BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis | Reuters 1 Min Read Oct 10 (Reuters) - Novartis AG: * NOVARTIS ANNOUNCES NEW DATA FROM THE FIRST DIRECT HEAD-TO-HEAD TRIAL TO DEMONSTRATE SUPERIOR EFFICACY OF GILENYA® OVER COPAXONE® IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS * SAYS DATA SHOW THAT GILENYA 0.5MG MET ITS PRIMARY ENDPOINT OF SIGNIFICANTLY REDUCING ANNUALIZED RELAPSE RATE COMPARED TO COPAXONE * SAFETY OF GILENYA OBSERVED IN ASSESS ACROSS BOTH DOSES WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF DRUG Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis Oct 10 (Reuters) - Novartis AG:
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- US FDA mandates label updates on CAR-T cancer therapies [Reuters]Reuters
- Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS [Yahoo! Finance]Yahoo! Finance
- Global Pediatric Drugs And Vaccines Market Size To Exceed USD 265.5 Billion By 2033 | CAGR of 8.04% [Yahoo! Finance]Yahoo! Finance
- Myasthenia Gravis (MG) Treatment Industry Forecast to 2030: A $2.5 Billion Market Dominated by Alexion Pharma, Grifols, Avadel Pharma, Novartis, Pfizer, AbbVie, and Roche [Yahoo! Finance]Yahoo! Finance
- Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/24 - Miss
NVS
Sec Filings
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- 1/31/24 - Form 6-K
- NVS's page on the SEC website